Diflucan

Χώρα: Αρμενία

Γλώσσα: Αγγλικά

Πηγή: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Δραστική ουσία:

fluconazole

Διαθέσιμο από:

Fareva Amboise

INN (Διεθνής Όνομα):

fluconazole

Δοσολογία:

150mg

Φαρμακοτεχνική μορφή:

capsules

Τρόπος διάθεσης:

Prescription

Αρχείο Π.Χ.Π.

1. NAMEOF THE MEDICINAL PRODUCT
DIFLUCAN
®
50 mg, capsules
DIFLUCAN
®
150 mg, capsules
DIFLUCAN
®
2 mg/ml, solution for infusion
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance: fluconazole DIFLUCAN capsules 50 mg and 150 mg
contains
active
ingredient
respectively
5
mg
and
150
mg.
The
solution
for
infusion
represents 2 mg/ml in a saline solution.
For the full list of excipients, please refer to section 6.1.
3. PHARMACEUTICAL FORM
Capsule, solution for intravenous infusion.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Therapy may be instituted before the results of the cultures and other
laboratory
studies are known; however, once these results become available,
anti-infective
therapy should be adjusted accordingly.
Fluconazole is indicated to treat the following diseases in adults:
- cryptococcal meningitis;
- coccidioidomycosis;
- invasive candidiasis;
-
mucosal
candidiasis,
including
oropharyngeal
candidiasis,
oesophageal
candidiasis, candiduria and chronic mucocutaneous candidiasis;
- chronic oral atrophic candidiasis (associated with dentures) with
insufficient
observation of oral hygiene or local treatment;
- acute and recurrent vaginal candidiasis if local treatment is not
administered;
- candidal balanitis if local treatment is not administered;
- dermatomycoses, including tinea pedis, tinea corporis, tinea cruris,
pityriasis
versicolor and candida infections of the skin if systemic treatment is
indicated;
- nail infection (onychomycosis) if no treatment with other medicinal
products has
been administered.
Fluconazole is indicated for prophylaxis of the following diseases in
adults:
- relapse of cryptococcal meningitis in patients with a high risk of
relapse;
- relapse of oropharyngeal candidiasis and oesophageal candidiasis in
HIV-positive
patients with a high risk of relapse;
- to reduce the incidence of recurrent vaginal candidiasis (four or
more episodes
per year);
- to prevent candida infections in patients with prolonged neutropenia
(for instance
haemoblastoma patients who are